Comparison of roxalrestat with erythropoietin in effect on micro-inflammatory factors and cardiac function indicators in patients with renal anemia receiving hemodialysis
Objective To compare roxadustat with erythropoietin in effect on micro-inflammatory factors and cardiac function indicators in patients with renal anemia receiving hemodialysis.Methods A total of 80 patients with renal anemia receiving hemodial-ysis in Chizhou Second People's Hospital from February 2023 to February 2024 were selected as the research subjects and divided into the observation group(n=40)and control group(n=40)according to the random number table method.The patients in the observation group were treated with roxadustat and those in the control group with erythropoietin.Micro-inflammatory factor indicators,anemia indicators,cardiac function indicators,and the occurrence of cardiovascular and cerebrovascular complications were compared between the two groups.Results After treatment,the levels of the micro-inflammatory factor indicators including interleukin-6(IL-6)and C-re-active protein(CRP)were significantly lower in the observation group than in the control((88.43±8.15)ng·L-1 vs(113.71±10.26)ng·L-1,(5.28±0.69)mg·L-1 vs(6.15±0.73)mg·L-1)(t=12.202,5.478,both P＜0.05).The levels of anemia indicators including red blood cell count(RBC),hemoglobin(Hb)and hematocrit(HCT)were remarkably higher in the observation group than in the control((3.47±0.68)×1012·L-1 vs(2.99±0.63)×1012·L-1,(111.39±7.58)g·L-1 vs(98.72±7.65)g·L-1,(37.80±5.47)%vs(29.69±4.83)%)(t=3.275,7.441,7.029,all P＜0.05).The levels of the cardiac function indicators including N-terminal pro-brain natriuretic peptide(NT-proB-NP)and cardiac troponin T(cTnT)were obviously lower in the observation group than in the control((124.43±10.15)pmol·L-1 vs(236.71±44.26)pmol·L-1,(0.64±0.10)μg·L-1 vs(0.96±0.15)μg·L-1)(t=15.638,11.226,both P＜0.05).The overall incidence rate of myocardial infarction,angina pectoris,stroke and heart failure was 7.50%(3/40)in the observation group and it was lower than that of 25.00%(10/40)in the control(χ2=4.501,P=0.034).Conclusion Compared with erythropoietin,roxadustat is more effective in reduc-ing inflammation and improving anemia in patients with renal anemia receiving hemodialysis.Meanwhile,it has less impact on cardiac function indicators and has a lower risk of cardiovascular and cerebrovascular complications.
HemodialysisErythropoietinRoxadustatMicro-inflammatory factorAnemiaCardiac function
万方数据
维普
